Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 133,810 | 144,687 | 54,518 | 7,020 | 0 |
| Other current assets | 0 | 0 | 2,824 | 1,526 | 0 |
| TOTAL | $136,416 | $148,517 | $58,539 | $8,927 | $0 |
| Non-Current Assets | |||||
| PPE Net | 739 | 781 | 822 | 708 | N/A |
| Other Non-Current Assets | 1,091 | 1,140 | 1,231 | 1,320 | 0 |
| TOTAL | $1,830 | $1,921 | $2,053 | $2,028 | $N/A |
| Total Assets | $138,246 | $150,438 | $60,592 | $10,955 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,716 | 4,852 | 2,426 | 2,088 | 0 |
| Accrued Expenses | 4,697 | 3,042 | 6,022 | 2,022 | 0 |
| TOTAL | $6,825 | $8,294 | $8,836 | $4,486 | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 663 | 783 | 901 | 5,974 | 0 |
| TOTAL | $663 | $783 | $901 | $5,974 | $N/A |
| Total Liabilities | $7,488 | $9,077 | $9,737 | $10,460 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 20,188 | 20,173 | 20,149 | N/A | N/A |
| Common Shares | 2 | 2 | 1 | 1 | 0 |
| Retained earnings | -54,335 | -42,299 | -31,542 | -19,650 | 0 |
| Other shareholders' equity | 0 | 0 | 75,722 | 19,941 | 0 |
| TOTAL | $130,758 | $141,361 | $50,855 | $495 | $0 |
| Total Liabilities And Equity | $138,246 | $150,438 | $60,592 | $10,955 | $0 |